I recently revisited the developments & fundamentals of CYP - Cynata Therapeutics. Seemingly, a well developed stem cell & regenerative medical stock in the biomedical sector. @Strawman first mentioned this company some years previous, which got my attention recently. With on-going catalyst trades & a shifting paradigm towards new world developments in the medical sector; 'could' Cynata now be flying under the radar? With similar like-minded companies i.e. Mesoblast being in favour within the market, plus additional developments in this space, will this also prove counter beneficial for 'other' industry leaders like Cynata(?)

Cynata have their first product licenced to FUJIFILM for; 'Graft vs Host Disease', whom are a major shareholder 'as well as'; Fidelity Int. & Board/Management. Cynata Therapeutics developed the 'Cymerus' platform which technologies was R&D by the University of Wisconsin-Madison USA & has potential too be used across a wide range of diseases. These are currently in various stages of pre-clinical, phase 2 & phase 3 trials. Cynata are estimated to have exposure to a +$11.6 billion market by 2025 & fundamentally this could prove an exciting prospect... lending itself to a new era of biomed & catalysts investors alike.

Definitely high risk, but now that i've added a bear case you can bet this thing will triple in value ;) Good luck Podcast!